Saturday, October 3, 2026

Mining

4 articles

Lion Copper Reports $14.77 Net Income as Going Concern Warnings Hit North American Junior Miners

Lion Copper Reports $14.77 Net Income as Going Concern Warnings Hit North American Junior Miners

Lion Copper and Gold Corp. reported $14.77 in net income, triggering catastrophic going concern assessments that mirror distress patterns across North American junior mining stocks. The pre-revenue Canadian explorer faces capital challenges common to global mineral exploration companies operating in capital-intensive sectors. Penny stock traders worldwide monitor such warnings as precursors to bankruptcy or dilutive recapitalization.

LM Salvado•
Black Angel Mine in Greenland Targets 2028 Start as Arctic Mining Accelerates

Black Angel Mine in Greenland Targets 2028 Start as Arctic Mining Accelerates

The Black Angel mining project in Greenland aims for Phase 1 operations in 2028, joining a wave of Arctic resource development as climate change opens new extraction opportunities. Infrastructure upgrades and technical validation are underway at the site, which previously operated from 1973 to 1990. The project reflects growing international interest in Greenland's mineral reserves amid global competition for critical resources.

ViaNews Editorial Team•
Alamos Gold Sets 2029 Timeline for Manitoba Mine as North American Gold Supply Tightens

Alamos Gold Sets 2029 Timeline for Manitoba Mine as North American Gold Supply Tightens

Canadian miner Alamos Gold targets December 2029 completion for its Lynn Lake project in Manitoba, positioning new supply against declining ore grades across North American mines. The timeline comes as central banks purchased 1,037 tonnes of gold in 2023, intensifying global demand pressures. Manitoba's top-quartile jurisdiction rating supports the four-year development schedule.

ViaNews Editorial Team•
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com